Engage Therapeutics

March 12, 2020

Engage Therapeutics Announces Phase 2b StATES Study of Staccato® Alprazolam for Seizure Cessation Meets Primary Endpoint

SUMMIT, N.J., March 12, 2020 — Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing an orally inhaled therapy designed to terminate an active epileptic […]
March 12, 2020

Abortive Seizure Agent Staccato Alprazolam Meets Primary End Point in Phase 2

The Engage Therapeutics product met its primary end point in the StATES study, with an onset of action for ceasing seizure activity of approximately 30 seconds, […]
March 12, 2020

Engage touts long-awaited positive data for its inhaler for seizures

From STAT News After scrabbling for early financing, Engage Therapeutics has some positive clinical data to show the world. It’s a particularly poignant win for Engage, […]
December 5, 2019

Engage Therapeutics Announces Two Poster Presentations at the American Epilepsy Society’s Annual Meeting

Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing an orally inhaled benzodiazepine for the acute termination of an ongoing prolonged focal, generalized or cluster seizure episode […]